EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney

Patrick R Walsh, Uttiya Basu, Tahsin Stefan Barakat, Bodo B Beck, Enrico Bertini, Vicky Brocklebank, Nuno Corderio, Jasmina Ćomić, Nora Abazi-Emini, Joel Fluss, Annette George, Marcus Bülow und 33 weitere

Kidney International · 2026

DOI: 10.1016/j.kint.2026.06.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2026. Verfasst von Patrick R Walsh und 44 weiteren Autor:innen. Beteiligte Einrichtung: National Renal Complement Therapeutics Centre, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK; Complement Therapeutic Research Gro…. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, RNA-Binding Proteins. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Research UK, Wellcome Trust, Macular Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components (EXOSC3 and EXOSC5) has been identified. The underlying pathogenesis remains unclear. METHODS: We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model (Exosc3KO) was used. RESULTS: Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. CONCLUSIONS: EXOSC3-TMA is a severe, early-onset, C5 inhibitor-resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesRNA-Binding ProteinsHumansFemaleMaleAnimalsMice, KnockoutChild, PreschoolAntibodies, Monoclonal, HumanizedInfantChildKidneyComplement Inactivating AgentsDrug ResistanceMiceApoptosisEurope

Stichwörter der Autor:innen

EXOSC3Shiga toxincomplementeculizumab-resistanthemolytic uremic syndromethrombotic microangiopathy

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedRNA-Binding ProteinsComplement Inactivating Agents

Autor:innen und Institutionen

  • National Renal Complement Therapeutics Centre, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK; Complement Therapeutic Research Group, Translational and Clinical Research Institute, Newcastle Universit…
  • Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
  • Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Institute of Human Genetics, Faculty of Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; Center for Rare and…
  • Research Unit of Neuromuscular and Neurodegenerative Disease, Bambino Gesu' Children's Research Hospital, IRCCS, Rome, Italy.
  • Department of Paediatrics, NHS Ayrshire and Arran, Kilmarnock, UK.

Förderung

  • Kidney Research UK
  • Wellcome Trust
  • Macular Society
  • Idorsia Pharmaceuticals
  • Medical Research Council
  • Catalyst Biosciences

Zitieren

APA

Walsh, P. R., Basu, U., Barakat, T. S., Beck, B. B., Bertini, E., Brocklebank, V., Corderio, N., Ćomić, J., Abazi-Emini, N., Fluss, J., George, A., Bülow, M., Gibson, B. G., Hambleton, S., Hoefele, J., Hunt, D., Ivanov, I., Johnson, S., Kotzaeridou, U., …, & Kavanagh, D. (2026). Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. Kidney International. https://doi.org/10.1016/j.kint.2026.06.028

Vancouver

Walsh PR, Basu U, Barakat TS, Beck BB, Bertini E, Brocklebank V, et al. Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. Kidney International. 2026. doi:10.1016/j.kint.2026.06.028

BibTeX
@article{Walsh2026,
  author = {Walsh, Patrick R and Basu, Uttiya and Barakat, Tahsin Stefan and Beck, Bodo B and Bertini, Enrico and Brocklebank, Vicky and Corderio, Nuno and Ćomić, Jasmina and Abazi-Emini, Nora and Fluss, Joel and George, Annette and Bülow, Marcus and Gibson, Beth G and Hambleton, Sophie and Hoefele, Julia and Hunt, David and Ivanov, Ivan and Johnson, Sally and Kotzaeridou, Urania and Laštůvková, Jana and Lunn, Andrew and Mallett, Grace and Pappworth, Isabel and Philippou, Helen and Platzer, Konrad and Robson, Julie and Šafka Brožková, Dana and Smith-Jackson, Kate and Sinha, Manish D and Thompson, Gemma and Wood, Katrina and Zanni, Ginevra and Prohászka, Zoltán and Laubova, Jana and Aranka, Judit and Bojtár, Zsüliet and Antal-Konya, Violetta and Bologa, Cristina and Karava, Vasiliki and Kamilari, Thessalia and Georgiadou, Elissavet and Tasic, Velibor and Markova, Petya and Marchbank, Kevin J and Kavanagh, David},
  title = {Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney},
  journal = {Kidney International},
  year = {2026},
  doi = {10.1016/j.kint.2026.06.028}
}
Kostenlos starten →